Tag: MMAE
AstraZeneca Enters License Agreement with KYM Biosciences for CMG901
AstraZeneca has signed an exclusive global license agreement with KYM Biosciences, a joint venture of Keymed Biosciences and Lepu Biopharma, for CMG901.
Advances in the Development of Dual-Drug Antibody Drug Conjugates
Antibody drug conjugates (ADCs) are touted for their ability to site selectively deliver a small molecule chemotherapeutic directly to a tumor cell, bypassing off target side effects from systemic circulation. To date, eleven ADCs have been FDA approved in the United States and >200 more in the clinical pipeline (clinicaltrials.gov).
Zai Lab to Commercialize and Expand Patient Access to Tisotumab...
Zai Lab, a patient focused, global biopharma company committed to driving the next wave of healthcare innovation confirmed that it had signed an exclusive collaboration and...
European Medicines Agency Recommends Approval of Enfortumab Vedotin Monotherapy for Locally...
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has confirmed its previously adopted positive opinion, recommending approval...
How an ADC with Intracellular Drug Release Properties Demonstrates Specific Cytotoxicity...
T-cell acute lymphoblastic leukemia or T-ALL is a biologically distinct form of leukemia. It's distinct from its B lymphoblastic or B-ALL counterpart and shows...
FDA Grants Breakthrough Therapy Designation to Enfortumab Vedotin-ejfv in First-Line Advanced...
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enfortumab vedotin-ejfv (Padcev™; Astellas Pharma and Seattle Genetics) in combination with...
Updated Results from Trial Shows Enfortumab Vedotin + Pembrolizumab to Shrink...
Updated findings from EV-103, a phase Ib/II clinical trials of enfortumab vedotin* (Padcev™; Astellas Pharma/Seattle Genetics) in combination with pembrolizumab (Keytruda®; Merck Sharp &...
Four Ways to Show Nonobviousness of ADC Inventions
As research continues to progress and the scientific community’s appreciation for the power of ADCs has grown, so have the numbers. FDA has now approved at least four ADCs, and hundreds more are in development. The number of patent applications has also grown, with the U.S. Patent and Trademark Office (USPTO) publishing over two hundred patent applications with claims to ADC inventions in the last two years alone.
ADCs – The Dawn of a New Era?
Two decades ago, ADCs were hailed as a major breakthrough, especially in the area of oncology therapeutics. The concept of delivering a potent drug payload directly to the site of the tumor for maximum effect with minimal damage caused to non-cancerous cells was viewed as, if not the Holy Grail of cancer treatment, at least a significant advance towards precision medicine. However, the concept has proved difficult to translate into clinical success.
New Hydrophilic Auristatin Payload Improves Antibody-Drug Conjugate Efficacy and Biocompatibility
Antibody-drug conjugates or ADCs, which link an antibody to a potent, small-molecule, cytotoxic, cell-killing, chemotherapeutic agent, use the target-specificity of monoclonal antibodies or antibody...
